O4, Jared Holz of Mizuho joined ‘Power Lunch’ on CNBC to talk about how to play biotech moving into 2026. Holz noted that ...

Biotech's 2025 rebound sets the stage for Denali Therapeutics and two peers, with key FDA decisions and pipeline catalysts ...

The long winter for biotech stocks is over. Shares have climbed to levels not seen since late 2021, buoyed by eye-popping ...

A run-up in biotech and drug stocks that sent valuations soaring through the second half of 2025 was looking a bit shaky on ...

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

With partner Eli Lilly’s help, the radiopharmaceutical drugmaker priced one of the sector’s largest new stock offerings in ...

Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics ( NTLA ) ...

A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an ...

By ending its agreement with ImmuneOnco, Instil is also handing back the other asset from the licensing deal: IMM27M, a next-gen anti-CTLA-4 antibody that ImmuneOnco had taken into phase 1 trials as a ...

A phase 3 study of Zenas BioPharma's autoimmune disease candidate has hit its primary endpoint. But, with the result falling ...